AstraZeneca aims to nearly double its 2023 sales to $80 billion by 2030, focusing on cancer and rare disease treatments. CEO Pascal Soriot highlighted twelve potential...
The pharmacist specializing in nuclear medicine will have to ensure the supply of radiopharmaceuticals to the centers dependent on the Andalusian Health Service (SAS) over the...